KPJ Healthcare could post sequentially stronger 2Q core net profit at 92 million ringgit (16% YoY, 28% sequential), driven by improved patient volume and revenue intensity, alongside margin recovery, per RHB IB analyst Eddy Do. Newer hospitals maturing and the third center of excellence launch may boost long-term growth. RHB maintains a buy rating with a 3.77 ringgit target price, though shares remain flat at 3.07 ringgit.

Apotex's U.S. segment underperforms post-public listing, with underlying sales dropping 8.6% to C$362.9 million (48.5% drop reported basis) due to competition and a Richmond Hill plant pause. CEO Jeff Watson attributes this to lost drug exclusivities (e.g., nilotinib) and operational delays. However, Canada’s 11.5% sales rise contrasts with U.S. struggles. Apotex emphasizes its Canadian manufacturing footprint as a tariff hedge and is expanding U.S. capacity via a Halo Pharmaceutical partnership.

Despite U.S. headwinds, Apotex remains bullish, leveraging North American onshoring initiatives and Canada’s strategic role. Shares fell 4.2%-4.7% to C$35.13-35.32. Analysts note the company’s focus on sterile injectables and lobbying for trade policies. The divergence between regions highlights risks in Apotex’s U.S. exposure versus Canadian strength.